VEGFA and cancer: VEGF is a potent pro-angiogenic factor that is critical for tumor-induced neo-angiogenesis and the current frontline anti-cancer drugs such as sunitinib, pazopanib and sorafinib all inhibits VEGF receptors and they have clearly shown positive clinical efficacy [6].